Britannia Life Sciences Inc (BLAB) AI Stock Analysis

• Market Cap: C$15.41M
• Dividend Yield: N/A
• Average Volume (3M): 90.85K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.85
• Revenue Growth: -3.93%
• EPS Growth: -575.24%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 162,254,330
• 10 Day Avg. Volume: 185,143
• 30 Day Avg. Volume: 90,847
• PEG Ratio: -0.81
• Price to Book (P/B): 1.93
• Price to Sales (P/S): 32.95
• P/FCF Ratio: -4.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

The overall stock score is primarily impacted by the company's weak financial performance, which includes declining revenues and negative cash flow. Technical analysis provides some support with positive price trends, but valuation concerns due to a negative P/E ratio and lack of dividend yield weigh heavily. The absence of earnings call insights and corporate events means these factors do not influence the score.

Britannia Life Sciences Inc Business Overview & Revenue Model

Company Description

Britannia Life Sciences Inc (BLAB) is a biotechnology company focused on advancing innovative solutions in the life sciences sector, particularly in drug development and healthcare technologies. The company specializes in research and development of pharmaceutical products, diagnostics, and therapeutic treatments that address unmet medical needs. BLAB leverages cutting-edge technologies and a team of experts to create a diverse portfolio of products aimed at improving patient outcomes and enhancing the efficiency of healthcare delivery.

How the Company Makes Money

Britannia Life Sciences Inc generates revenue primarily through the commercialization of its pharmaceutical products and diagnostics. The company adopts a multi-faceted revenue model that includes direct sales of its products to healthcare providers and institutions, licensing agreements with larger pharmaceutical companies for the development and distribution of its innovations, and collaborative research partnerships that provide funding and shared resources. Key revenue streams include sales from proprietary therapeutics, royalties from licensed products, and grant funding from governmental and private research initiatives. Strategic partnerships with other biotech firms and research institutions also enhance BLAB's earning potential by expanding its market reach and facilitating innovation.

Britannia Life Sciences Inc Financial Statement Overview

Summary

The financial performance is weak due to significant revenue decline and operational inefficiencies. Despite a high net profit margin, negative EBIT and EBITDA margins indicate instability. The balance sheet shows manageable leverage but past financial instability. Cash flow management is poor with negative cash flows and declining growth.

Income Statement

The income statement shows significant volatility. The company experienced a drastic revenue decline of 94.86% in the most recent year, which is concerning. Despite this, the net profit margin is notably high at 20.02%, indicating some profitability. However, negative EBIT and EBITDA margins suggest operational inefficiencies. Overall, the income statement reflects instability with some profitability potential.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.29, indicating manageable leverage. However, the return on equity is extremely high at 117.33%, which may be due to the low equity base rather than operational efficiency. The equity ratio is not provided, but the overall financial health appears fragile due to past high leverage and equity fluctuations.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a significant decline in free cash flow growth by 500.37%. The operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is 1.0, suggesting that free cash flow aligns with net income, but overall cash flow management appears weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-1.23M	369.28K	7.57M	6.40M	7.30M	1.42M
Gross Profit	-1.14M	27.33K	4.85M	4.64M	5.26M	1.17M
EBITDA	-4.56M	-4.39M	-1.90M	6.95M	-10.77M	-1.62M
Net Income	7.44M	7.39M	-4.77M	5.08M	-15.46M	-157.16K
Balance Sheet
Total Assets	9.81M	11.61M	22.26M	23.55M	21.09M	21.45M
Cash, Cash Equivalents and Short-Term Investments	6.14M	7.85M	1.32M	2.60M	1.63M	828.32K
Total Debt	1.82M	1.86M	7.29M	8.41M	5.19M	10.55M
Total Liabilities	4.26M	5.31M	15.59M	12.49M	15.61M	18.79M
Stockholders Equity	5.55M	6.30M	2.44M	7.02M	1.35M	-202.32K
Cash Flow
Free Cash Flow	-3.98M	-2.62M	1.75M	874.41K	2.71M	-543.49K
Operating Cash Flow	-3.78M	-2.62M	2.09M	1.22M	2.80M	-586.58K
Investing Cash Flow	11.11M	11.27M	-1.44M	-3.32M	653.95K	-4.91M
Financing Cash Flow	-1.68M	-2.17M	-1.97M	2.95M	-2.58M	6.20M

Britannia Life Sciences Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Positive. The current price of 0.1 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.08, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 56.73 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BLAB.

Britannia Life Sciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	48 Neutral	C$15.41M	―	―	―	-3.93%	-575.24%
KNE	41 Neutral	C$6.65M	―	―	―	―	―
BIOV	29 Underperform	$7.29M	―	―	―	―	25.09%
BETR	21 Underperform	$9.87M	―	―	―	―	85.61%

Britannia Life Sciences Inc Corporate Events

Britannia Life Sciences Strengthens Financial Position with Strategic Sale

Britannia Life Sciences Inc. has completed the sale of its UK operating subsidiary, Advanced Development and Safety Laboratories Inc., resulting in net proceeds of approximately $13 million. The company is prioritizing strategic capital allocation to optimize shareholder returns and support sustainable growth. Britannia is also focusing on its investment in Britannia Mining Solutions, recognizing its potential to drive value and align with the company’s strategic goals.